These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29451467)

  • 1. Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients.
    Morrow T
    Manag Care; 2018 Feb; 27(2):30-32. PubMed ID: 29451467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab (Hemlibra) for subcutaneous prophylaxis in hemophilia A.
    Med Lett Drugs Ther; 2019 May; 61(1572):77-79. PubMed ID: 31169801
    [No Abstract]   [Full Text] [Related]  

  • 3. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 5. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.
    Santagostino E; Mancuso ME; Novembrino C; Solimeno LP; Tripodi A; Peyvandi F
    Haematologica; 2019 Aug; 104(8):e380-e382. PubMed ID: 30923092
    [No Abstract]   [Full Text] [Related]  

  • 7. Bispecific antibody mimicking factor VIII.
    Nogami K
    Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valoctocogene roxaparvovec (Roctavian) - a gene therapy for severe hemophilia A.
    Med Lett Drugs Ther; 2023 Oct; 65(1686):157-158. PubMed ID: 37755692
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemophilia Therapy--Navigating Speed Bumps on the Innovation Highway.
    DiMichele DM
    N Engl J Med; 2016 May; 374(21):2087-9. PubMed ID: 27223151
    [No Abstract]   [Full Text] [Related]  

  • 10. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A.
    Lippi G; Favaloro EJ
    Adv Clin Chem; 2019; 88():151-167. PubMed ID: 30612605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altuviiio - a longer-acting factor VIII product for hemophilia A.
    Med Lett Drugs Ther; 2023 May; 65(1675):67-68. PubMed ID: 37155249
    [No Abstract]   [Full Text] [Related]  

  • 12. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
    Dargaud Y; Lienhart A; Janbain M; Le Quellec S; Enjolras N; Negrier C
    Haematologica; 2018 Apr; 103(4):e181-e183. PubMed ID: 29472355
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort.
    Batsuli G; Wheeler AP; Weyand AC; Sidonio RF; Young G
    Am J Hematol; 2023 Oct; 98(10):E285-E287. PubMed ID: 37471655
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies-generational enhancement.
    Lillicrap D; Lenting P
    J Thromb Haemost; 2024 Feb; 22(2):352-355. PubMed ID: 38309809
    [No Abstract]   [Full Text] [Related]  

  • 16. The ongoing imperative for immune tolerance induction in inhibitor management.
    Aledort LM
    Haemophilia; 2019 Mar; 25(2):183-186. PubMed ID: 30748063
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of factor VIII inhibitors.
    Dimichele DM
    Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A bispecific antibody mimicking factor VIII in hemophilia A therapy].
    Nogami K
    Rinsho Ketsueki; 2016 Jun; 57(6):709-14. PubMed ID: 27384849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hemophilia A with actor VIII concentrate in urological operations and injuries of the urinary tract].
    Brühl P; Weibbach L; Brackmann HH
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):401-4. PubMed ID: 804604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.